SIGNAL // LOADING
Loading page
Glossary term
Tirzepatide
Also known as Mounjaro - Zepbound
The dual GIP/GLP-1 agonist behind Mounjaro and Zepbound - roughly 20.9% average weight loss in SURMOUNT-1.
Tirzepatide activates both the GIP and GLP-1 receptors, which is why it outperforms pure GLP-1 drugs on most metrics. SURMOUNT-1 showed ~20.9% mean weight loss at 72 weeks on 15 mg vs ~3% on placebo; SURPASS-2 showed a ~2.0-2.4% A1c reduction at max dose in type 2 diabetes. Dosing starts at 2.5 mg weekly and titrates through five steps. Hard contraindications: personal or family MTC, MEN2, active pancreatitis, pregnancy. Book the assessment and we'll check eligibility against your labs.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
External references
Related
Connected context
Related terms
Related guides
GLP-1 eligibility explained: who qualifies, who doesn't, and whyTirzepatide vs semaglutide: how to think about the choiceWhat a comprehensive metabolic panel actually tells youProvider-reviewed care vs DIY supplementation: when each makes sensePCOS labs: the markers that actually drive the planGLP-1 side effects: what's normal, what needs review, what stops the protocolHolding the loss after GLP-1: protein, training, and the maintenance planFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by yearsCreatine, protein, and the two supplements that actually moved your labsWeight-loss plateaus on GLP-1: what to change first